Phase 2 Study of Yimitasvir Phosphate Capsules
A Multicenter, Randomized, Parallel Assigned, Open-label Study to Investigate the Efficacy and Safety of Yimitasvir Phosphate (DAG181)/Sofosbuvir(SOF) Combination for 12 Weeks in Subjects With Chronic Genotype 1 HCV Infection
研究概览
详细说明
A phase 2, multicenter, randomized, parallel Assigned, open-label study to explore the safety, tolerability and antiviral activity of DAG181/SOF combination for 12 weeks in adult subjects with chronic genotype 1 HCV infection.
Approximately 120 HCV genotype 1 subjects without cirrhosis will be enrolled, treatment-experienced subjects are ≤20%, all subjects will be randomized (1:1) to one of the following two treatment groups by IWRS (Medidata Balance): a) DAG181 100 mg/ SOF 400 mg once daily for 12 weeks, b) DAG181 200 mg/ SOF 400 mg once daily for 12 weeks. Randomization will be stratified by "treatment-naive" or "treatment-experienced".
研究类型
注册 (实际的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
Beijing
-
Beijing、Beijing、中国、100034
- Peking University first hospital
-
Beijing、Beijing、中国、100069
- Beijing Youan Hospital,Capital Medical University
-
Beijing、Beijing、中国、100044
- Peking University People's Hospital
-
-
Gansu
-
Lanzhou、Gansu、中国、730000
- The First Hospital of Lanzhou University
-
-
Guangdong
-
Guangzhou、Guangdong、中国、510515
- Nanfang Hospital of Southern Medical University
-
Guangzhou、Guangdong、中国、510060
- Guangzhou Eighth People's Hospital
-
-
Hainan
-
Haikou、Hainan、中国、570311
- Hainan General Hospital
-
-
Hebei
-
Shijiazhuang、Hebei、中国、050051
- The Third Hospital of Hebei Medical University
-
-
Hubei
-
Wuhan、Hubei、中国、430060
- Renmin Hospital of Wuhan University
-
Wuhan、Hubei、中国、430022
- Union Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology
-
Wuhan、Hubei、中国、430030
- Tongji Hospital Affiliated to Tongji Medical College of Huazhong University Science & Technology
-
-
Hunan
-
Changsha、Hunan、中国、410008
- Xiangyan Hospital, Central South University
-
-
Jiangsu
-
Nanjing、Jiangsu、中国、210003
- The Second Hospital of Nanjing
-
-
Jiangxi
-
Nanchang、Jiangxi、中国、330006
- The First Affiliated Hospital Of Nanchang University
-
-
Jilin
-
Chang Chun、Jilin、中国、130021
- The First Hospital of Jilin University
-
-
Shanxi
-
Xi'an、Shanxi、中国、710038
- Tangdu Hospital
-
-
Sichuan
-
Chengdu、Sichuan、中国、610041
- West China Hospital, Sichuan University
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Willing and able to provide written informed consent;
- Male or female, age≥18 years;
A female subject is eligible to enter the study if it is confirmed that she is:
- Of non-childbearing potential (i.e., women who have had a hysterectomy, have both ovaries removed or medically documented ovarian failure, or are postmenopausal-women > 50 years of age with cessation (for≥12 months) of previously occurring menses), or
- Of childbearing potential (Women≤50 years of age with amenorrhea will be considered to be of childbearing potential). These women must have a negative serum pregnancy test at screening, and must use specific contraceptive methods from screening until 4 weeks after last dose of study drugs, such as complete abstinence from intercourse, vaginal ring, cervical cap or contraceptive diaphragm, IUD, etc.
- All male study subjects must agree to consistently and correctly use specific contraceptive methods with their female partner from screening until 4 weeks after last dose of study drugs(except of surgical sterilization), such as complete abstinence from intercourse, condom, and their female partner use contraceptives , vaginal ring , cervical cap or contraceptive diaphragm, IUD, etc.
- Male subjects must agree to refrain from sperm donation from the date of screening until 4 weeks after the last dose of study drugs;
- Body mass index (BMI)≥18.0 and≤32.0 kg/m2, and Weight≥40 kg;
Confirmation of chronic HCV infection documented by either:
- A positive anti-HCV antibody test or positive HCV RNA or positive HCV genotyping test at least 6 months prior to the Baseline/Day 1 visit, or
- A liver biopsy performed prior to the Baseline/Day 1 visit with evidence of chronic HCV infection.
- Serological detection of anti-HCV antibodies was positive at screening;
- HCV RNA≥1×104 IU/mL at Screening;
- HCV genotype 1a, 1b, or mixed 1a/1b at screening as determined by the Central Laboratory;
Classification as treatment naive or treatment experienced:
- Treatment naive is defined as having never been exposed to approved or experimental HCV-specific direct-acting antiviral agents or prior treatment of HCV with interferon (with or without ribavirin);
- Treatment experienced is defined as prior treatment failure to a regimen containing interferon (IFN-α,β or Peg-IFN±RBV) that was completed at least 2 months prior to screening. and the subject's medical records must include sufficient detail of prior virologic failure to allow for categorization of prior response, as either:
i) Non-Responder: Decrease of HCV RNA<2 log at week 12 compared to baseline; ii) Partially-Responder: Decrease of HCV RNA>2 log at week 12 compared to baseline, and detectable HCV RNA levels within week 12 and week 24; iii) Breakthrough/Relapse: Subject achieved undetectable HCV RNA levels (HCV RNA < LLOQ) during treatment, but did not achieve sustained virologic response (SVR); iv) Intolerance: Subjects have discontinued interferon-based treatment due to intolerance which proved by chief complaint or medical records.
Absence of cirrhosis is defined as any one of the following:
- Liver biopsy within 2 years of Screening or at Screening showing absence of cirrhosis (e.g. Metavir score=0-3 or Ishak score<5), or
- Fibroscan within 6 months of Screening or at Screening with a result of ≤12.5 kPa.
liver biopsy results will supersede fibroscan results and be considered definitive.
- Subject must be able to comply with the dosing instructions for study drug administration and able to complete the study schedule of assessments.
Exclusion Criteria:
Subjects who meet any of the following exclusion criteria are not to be enrolled in this study:
Current or prior history of any of the following:
- Clinical hepatic decompensation (i.e., ascites, encephalopathy or variceal hemorrhage);
- Chronic liver disease of a non-HCV etiology (Including but not limited to hemochromatosis, Wilson's disease,alfa-1 antitrypsin deficiency);
- Significant cardiac disease(Including but not limited to myocardial infarction, bradycardia) ;
- Significant pulmonary disease;
- Malabsorption syndrome or gastrointestinal disorder or post operative condition that could interfere with the absorption of the study drug;
- Central nervous system trauma, epilepsy, stroke or transient ischemic attack;
- Psychiatric illness or psychological disease or relevant medical history;
- Malignancy diagnosed before signing the informed consent form ( except for specific cancers that have been cured by surgical resection (basal cell skin cancer, etc) or cervical carcinoma in situ are allowed). subjects under evaluation for malignancy are not eligible;
- Solid organ transplantation;
- Subjects have any other medical disorder that may interfere with subjects treatment, assessment or compliance with the protocol.
Subjects has the following laboratory parameters at screening:
- ALT > 10×the upper limit of normal (ULN);
- AST > 10×ULN;
- Total bilirubin> 1.5 × ULN;
- Albumin< 3.5 g/dL;
- AFP>100 ng/mL; If 20 ng/mL≤AFP≤100 ng/mL, a liver ultrasound examination is required to exclude subjects suspected of hepatocellular carcinoma;
- INR > 1.5 x ULN;
- Hemoglobin<11 g/dL for female subjects; <12 g/dL for male subjects;
- Platelets<90 x109/L;
- Neutrophil absolute count< 1.5 ×109/L;
- HbA1c > 8.5%;
- Creatinine clearance (CLcr) <50 mL /min as calculated by the Cockcroft-Gault equation;
- HBsAg serology test results were positive;
- HIV antibody test results were positive.
- Screening ECG with clinically significant abnormalities;
- Prior exposure to approved or experimental HCV-specific direct-acting antiviral agent;
- Use of any prohibited concomitant medications;
- Significant drug allergy, or known hypersensitivity to DAG181, SOF and its metabolites, or formulation recipients;
- A positive drug screen at screening will exclude subjects unless it can be explained by non-prescription drug or prescribed medication; the diagnosis and prescription must be approved by the investigator;
- Pregnant or nursing female or male with pregnant female partner.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
实验性的:SOF+DAG181 100 mg
Patients with genotype 1 HCV infection without cirrhosis will receive SOF+DAG181 100 mg for 12 weeks.
|
每天口服一次 400 毫克片剂
其他名称:
Capsule administered orally once daily
其他名称:
|
实验性的:SOF+DAG181 200 mg
Patients with genotype 1 HCV infection without cirrhosis will receive SOF+DAG181 200 mg for 12 weeks.
|
每天口服一次 400 毫克片剂
其他名称:
Capsule administered orally once daily
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Percentage of subjects with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)
大体时间:Posttreatment Week 12
|
SVR12 was defined as HCV RNA < the lower limit of quantitation (LLOQ) at 12 weeks after stopping study treatment
|
Posttreatment Week 12
|
Safety and tolerability were evaluated based on adverse event monitoring, laboratory tests, 12-lead ECG assessments, vital signs measurements and physical examinations.
大体时间:Up to posttreatment week 24
|
Up to posttreatment week 24
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Percentage of subjects with sustained virologic response 4, 8 and 24 weeks after discontinuation of therapy (SVR4,SVR8 and SVR24)
大体时间:Posttreatment Weeks 4,8 and 24
|
SVR4,SVR8 and SVR24 were defined as HCV RNA < the lower limit of quantitation (LLOQ) at 4, 8 and 24 weeks after stopping study treatment, respectively.
|
Posttreatment Weeks 4,8 and 24
|
Percentage of subjects with HCV RNA < the lower limit of quantitation (LLOQ) while on treatment
大体时间:Baseline to week 12
|
Baseline to week 12
|
|
The time to first achieve "HCV RNA < the lower limit of quantitation (LLOQ)" while on treatment
大体时间:Baseline to week 12
|
Baseline to week 12
|
|
HCV RNA change from baseline
大体时间:Up to posttreatment week 24
|
Up to posttreatment week 24
|
|
Percentage of subjects with virologic failure
大体时间:Up to posttreatment week 24
|
Virologic failure was defined as:
|
Up to posttreatment week 24
|
Viral resistance
大体时间:Up to posttreatment week 24
|
Viral resistance to DAG181 and/or SOF during treatment and after cessation of treatment
|
Up to posttreatment week 24
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
慢性丙型肝炎病毒感染的临床试验
-
Assistance Publique Hopitaux De Marseille未知
-
National Institutes of Health Clinical Center (CC)Bristol-Myers Squibb; National Institute of Allergy and Infectious Diseases (NIAID)完全的
-
University of California, IrvineUniversity of California, Los Angeles; National Institute on Minority Health and Health Disparities...完全的
-
National Taiwan University Hospital未知
-
Fundacion para la Investigacion Biomedica del Hospital...Instituto de Salud Carlos III完全的
特种部队的临床试验
-
McMaster UniversityAgency for Healthcare Research and Quality (AHRQ); Grading of Recommendations Assessment, Development...完全的
-
Humanity and Health Research CentreBeijing 302 Hospital; Nanfang Hospital of Southern Medical University招聘中
-
Sanjay Gandhi Postgraduate Institute of Medical...Ram Manohar Lohia Institute of Medical Sciences, Lucknow终止
-
Humanity and Health Research CentreUniversity of Maryland; Emory University; Beijing 302 Hospital撤销
-
Stanford UniversityGilead Sciences完全的
-
Kirby Institute完全的
-
Gilead Sciences终止
-
Gilead Sciences终止丙型肝炎病毒感染美国, 英国, 澳大利亚, 德国, 意大利, 新西兰, 比利时, 波兰, 俄罗斯联邦